Protara Therapeutics Introduces Breakthrough TARA-002 for the Treatment of Paediatric Lymphatic Malformations
Protara Therapeutics has introduced TARA-002 for the treatment of paediatric patients with macrocystic and mixed cystic lymphatic malformations (LMs), a rare congenital disorder.
TARA-002 is an inactivated and genetically distinct strain of Streptococcus pyogenes designed to retain immune-stimulating properties. By triggering a localised immune response within the malformation, TARA-002 aims to reduce cyst size and improve clinical outcomes in affected children.
The Breakthrough Therapy and Fast Track Designations are supported by clinical data from ongoing studies evaluating TARA-002 in paediatric patients with lymphatic malformations. Available findings have been reviewed by the U.S. Food and Drug Administration as part of the expedited programme assessment. Safety and activity observations from the clinical development programme have informed the regulatory decision.
TARA-002 had previously received Rare Paediatric Disease Designation from the U.S. Food and Drug Administration. In addition, the therapy has been accepted into the FDA’s Chemistry, Manufacturing and Controls (CMC) Development and Readiness Pilot Programme to support manufacturing readiness during continued clinical development. Further regulatory interactions are anticipated to determine the next steps in the development pathway.
Lymphatic malformations are rare abnormalities of the lymphatic vessels that occur due to improper development of the lymphatic system. The condition is commonly present at birth and is usually diagnosed in early childhood, with most cases identified before the age of three. LMs frequently affect the head and neck region and may cause airway obstruction, recurrent infections, bleeding, and functional or cosmetic complications. Current treatments often focus on symptom management, underscoring the need for more effective targeted therapies.
TARA-002 is among the first investigational therapies to receive both U.S. FDA Breakthrough Therapy and Fast Track Designations for the treatment of paediatric lymphatic malformations, offering a potential new therapeutic option for children living with this rare congenital disorder.
